Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1Phase 1 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Leukemia, Myeloid, Acute 97Myelodysplastic Syndromes 73Precursor Cell Lymphoblastic Leukemia-Lymphoma 61Leukemia, Lymphocytic, Chronic, B-Cell 59Leukemia 55Lymphoma, Non-Hodgkin 45Lymphoma 43Leukemia, Myelogenous, Chronic, BCR-ABL Positive 43Multiple Myeloma 42Hodgkin Disease 38Hematologic Neoplasms 35Myeloproliferative Disorders 24Melanoma 22Lymphoma, Mantle-Cell 18Recurrence 17Lymphoma, Follicular 17Neoplasms 16Lymphoma, Large B-Cell, Diffuse 15Primary Myelofibrosis 14Lymphoma, B-Cell 14Burkitt Lymphoma 14Anemia, Refractory, with Excess of Blasts 14Lymphoma, B-Cell, Marginal Zone 13Leukemia, Myelomonocytic, Chronic 13Leukemia, Biphenotypic, Acute 13Graft vs Host Disease 13Hematologic Diseases 12Anemia, Aplastic 11Skin Neoplasms 10Ovarian Neoplasms 10

Interventions

Oxaliplatin 26Gemcitabine 22Fluorouracil 17Capecitabine 16Leucovorin 15pembrolizumab 14Docetaxel 14Cisplatin 13Bevacizumab 12Radiotherapy 8Paclitaxel 8Irinotecan 8Trastuzumab 7Pemetrexed 6Carboplatin 6130-nm albumin-bound paclitaxel 6durvalumab 5cemiplimab 5Erlotinib Hydrochloride 5Sunitinib 4Ramucirumab 4Metformin 4Gefitinib 4trastuzumab deruxtecan 3tislelizumab 3cabozantinib 3atezolizumab 3Taxes 3Sorafenib 3Panitumumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Adenocarcinoma × fludarabine × Clear all
NCT02133196 2026-06-05

T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
85 enrolled
Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms, Neoplasm Metastasis, Carcinoma, Adenosquamous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡